Scott Dunseth Myers - Feb 6, 2023 Form 4 Insider Report for Viridian Therapeutics, Inc.\DE (VRDN)

Role: Chief Executive Officer, Director
Signature: /s/ Lara Meisner, Attorney-in-Fact for Scott Myers
Stock symbol: VRDN
Transactions as of: Feb 6, 2023
Transactions value $: $0
Form type: 4
Date filed: 2/7/2023, 05:55 PM
Previous filing: Jan 4, 2023
Next filing: Mar 13, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VRDN	Common Stock	Award	$0	+250K		$0.00	250K	Feb 6, 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VRDN	Stock Option (Right to Buy)	Award	$0	+1M		$0.00	1M	Feb 6, 2023	Common Stock	1M	$35.80	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units that vest 25% on February 6, 2024 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date.
F2	The option vests 25% on February 6, 2024 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date.